Follow Flash Finance FollowTelegram
19tech score
/ 100

Ambalal Sarabhai (AMBALALSA) — Technical Setup

₹35.33 +0.97%   Weak Downtrend Normal Volatility Strong bearish

As of 2026-11-02 close Sector: Pharma Pharmaceuticals All technical setups →

Summary

Ambalal Sarabhai is in a weak downtrend on the daily chart. RSI(14) is 38.8, MACD is below its signal line, ADX reads 21. Volume in the latest session was 0.5× its 20-day average. Over three months it has outperformed the Nifty 50 by 5.3 percentage points. Nearest support is ₹33.55 and resistance ₹36.92. Its technical score is 19/100 (strong bearish).

Trend (daily)
Bearish
Trend (weekly)
—
Trend (monthly)
—
RSI (14)
38.80
MACD
Bearish
ADX (14)
20.58
Volume vs 20d avg
0.48×
Support
₹33.55 (−5.0%)
Resistance
₹36.92 (+4.5%)
RS vs Nifty (3M)
+5.27%
RS rating
71.00

🧮 How the 19/100 is built

Five components, 20 points each. Every rule is shown with the points it earned — the score describes the chart as it stands today; it is not a prediction.

Trend0/20
  • Close above 20-day EMA (-4.51)0/3
  • 20-day EMA above 50-day EMA0/3
  • 50-day EMA above 200-day EMA0/3
  • Close above 200-day SMA0/3
  • SuperTrend (10,3) pointing up0/3
  • ADX ≥ 20 with +DI above −DI (trend has strength) (20.58)0/3
  • Weekly trend up (above a rising 30-week average)0/2
Momentum4/20
  • RSI(14) in the bullish zone (55-70 best) (38.80)0/6
  • MACD line above its signal line0/4
  • MACD line above zero (-1.36)0/3
  • 12-day rate of change positive (-9.25)0/3
  • Stochastic %K above %D2/2
  • Outperforming the Nifty 50 over 3 months (5.27)2/2
Volume0/20
  • On-balance volume rising over 20 sessions0/5
  • Chaikin Money Flow (20) positive (-0.03)0/5
  • More volume on up days than down days (20 sessions) (0.92)0/5
  • Close above 20-day VWAP (-6.44)0/5
Volatility9/20
  • Daily range (ATR%) contained — ≤2.5% scores full (4.83)2/6
  • Price in the upper half of its Bollinger Bands (0.23)2/5
  • Shallow drawdown from the 52-week high (-29.31)1/5
  • Volatility contracting (20-day volatility below its 6-month median) (20.50)4/4
Support / Resistance6/20
  • Room to the next resistance (≥8% scores full) (4.51)3/5
  • Support close below (a tight, definable stop) (5.05)3/5
  • Broke above a 20-day high in the last 5 sessions0/5
  • Within 5% of the 52-week high (-29.31)0/5

🧭 Regime: Weak Downtrend

Normal Volatility — Bollinger width is in the 77th percentile of the last six months.

Suits: Defensive. Price is below its averages. Oversold bounces happen, but the path of least resistance is lower — wait for a base.

Classified from ADX, the 20/50-day EMA stack and price's distance from the 50-day average; volatility from band-width and ATR expansion.

Opens the AI Backtester with the SuperTrend (10,3) rules for AMBALALSA — supertrend (10,3) flips to an uptrend.

🕰️ Multi-timeframe

TimeframeTrendRSI (14)MACD hist.
Monthly———
Weekly———
Daily▼ Bearish38.80-0.15

Weekly: close vs a rising 30-week average (Weinstein). Monthly: close vs the 10-month average. Weekly SuperTrend: —, weekly ADX —.

📶 Volume & VWAP

Relative volume
0.48×
5d / 20d volume
0.58×
Volume ROC (10d)
-30.63%
Up/down volume
0.92×
OBV (20d)
Falling / flat
Chaikin MF (20)
-0.03
VWAP 20d
₹37.76 (-6.44%)
VWAP 50d
₹41.36 (-14.58%)
Anchored VWAP · 52W low
₹41.98 (-15.84%)
Anchored VWAP · 52W high
₹43.80 (-19.34%)
Anchored VWAP · YTD
₹39.16 (-9.78%)
Avg turnover (20d)
₹0.15 Cr

VWAPs are computed from daily bars (typical price × volume), not intraday ticks. Volume has dried up to under 60% of normal.

💪 Relative strength

vs Nifty 1M
-14.27%
vs Nifty 3M
+5.27%
vs Nifty 6M
+13.60%
vs Nifty 1Y
—
RS rating
71.00
Mansfield RS
—
vs Pharma index 3M
-0.74%
vs sector peers 3M
+1.78%

AMBALALSA ÷ Nifty 50, rebased to 100 a year ago. Rising = outperforming.

🧱 Support & resistance

Clustered swing highs and lows from the last year; “touches” is how many swings formed the level.

LevelPriceDistanceTouches
Resistance₹42.42+20.1%2
Resistance₹40.40+14.3%1
Resistance₹38.50+9.0%1
Resistance₹36.92+4.5%2
Close₹35.33—
Support₹33.55−5.0%2
Support₹30.45−13.8%4

52-week range: ₹30.15 – ₹49.98 (-29.31% from the high).

🌀 Fibonacci

Measuring the up-swing from ₹30.15 (2026-07-23) to ₹49.98 (2026-08-10). Price has retraced 73.9% of it.

RatioPriceDistance
23.6% retracement₹45.30+28.2%
38.2% retracement₹42.40+20.0%S/R confluence
50.0% retracement₹40.06+13.4%S/R confluence
61.8% retracement₹37.73+6.8%
78.6% retracement₹34.39-2.6% nearest
127.2% extension₹55.37+56.7%
161.8% extension₹62.23+76.2%
200.0% extension₹69.81+97.6%

Next Fibonacci time zone: 89 sessions from the swing start ≈ 2026-11-30 (approximate — exchange holidays are not modelled).

🕯️ Candlesticks (last 5 sessions)

  • Doji 2026-11-02 neutral Weak · 20

Quality combines the pattern's reliability with its context: prior trend, volume, a support/resistance level and RSI.

↗️ Divergences

No regular divergence on RSI, MACD, OBV, MFI or Stochastic at the latest swings.

🏭 Pharma peers by technical score
Stock Close Chg Score Trend regimeRS rating (1-99)
DIVISLABDivi's Laboratories Limited ₹9,945.50 +1.69% 94 Uptrend 92.00
ACUTAASAcutaas Chemicals Limited ₹3,892.60 -2.77% 87 Uptrend 96.00
SMSPHARMASMS Pharmaceuticals Limited ₹504.15 -1.41% 87 Strong Uptrend 92.00
CORONACORONA Remedies Limited ₹2,171.10 +1.00% 86 Uptrend 84.00
ZYDUSLIFEZydus Lifesciences Limited ₹1,240.50 -0.40% 85 Uptrend 85.00
PPLPHARMAPiramal Pharma Limited ₹239.92 +0.42% 83 Strong Uptrend 90.00
DRREDDYDr. Reddy's Laboratories Limited ₹1,342.00 -0.74% 82 Strong Uptrend 76.00
AARTIDRUGSAarti Drugs Limited ₹453.80 +4.27% 81 Strong Uptrend 77.00
ALIVUSAlivus Life Sciences Limited ₹1,447.60 +2.28% 81 Strong Uptrend 92.00
GLANDGland Pharma Limited ₹3,066.60 -0.95% 80 Uptrend 94.00
🔗 More on AMBALALSA

⚠️ Educational technical analysis computed automatically from end-of-day NSE prices — not investment advice. Flash Finance is not SEBI-registered. Indicators describe what price has done; they do not predict what it will do. Verify levels on a live chart and manage risk before acting.

⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI